Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Miller, Jeffrey S., MD |
---|---|
Information provided by: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT00167167 |
In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.
Condition | Intervention |
---|---|
Leukemia, Myeloid, Chronic AML MDS Leukemia, Lymphocytic, Acute |
Procedure: Donor Lymphocyte Infusion |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-Derived Lymphocytes |
Estimated Enrollment: | 100 |
Study Start Date: | December 1995 |
Estimated Study Completion Date: | February 2010 |
Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
We will collect immune cells or lymphocytes from the donor's blood using a cell separator. The blood lymphocytes will be given to the subjects through a catheter. If the subjects have no complications of the first course of infusions, we may decide to give them "lymphocytes" aa second time while subjects are in remission in an attempt to prevent their disease from relapsing. A bone marrow test will be taken prior to infusion of lymphocytes as part of the clinical evaluation to receive this treatment. After lymphocyte infusions, a bone marrow will be examined about every three months for the first year to monitor progress from this therapy.
Ages Eligible for Study: | 1 Year to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Minnesota | |
University of Minnesota Medical Center | |
Minneapolis, Minnesota, United States, 55455 |
Principal Investigator: | Jeffrey Miller, MD | University of Minnesota Medical Center |
Responsible Party: | University of Minnesota Medical Center ( Jeffrey Miller, MD ) |
Study ID Numbers: | 9510M10277, MT1995-24 |
Study First Received: | September 9, 2005 |
Last Updated: | June 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00167167 |
Health Authority: | United States: Institutional Review Board |
Donor Lymphocyte Infusion relapse post-transplant |
Lymphatic Diseases Leukemia Leukemia, Lymphoid Immunoproliferative Disorders Precursor Cell Lymphoblastic Leukemia-Lymphoma Hematologic Diseases |
Myeloproliferative Disorders Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Bone Marrow Diseases Lymphoproliferative Disorders Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |